Full name
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
NCT Number
NCT04937387
Geography
Non-US
Locations
China
Primary Endpoints
Cohorts 1 and 2: Change from Baseline in trough Forced expiratory volume in 1 second (FEV1) (Liters). Baseline and at Week 12
External Link
https://clinicaltrials.gov/study/NCT04937387
Order
4
Disease
Version
Phase
3